Cargando…
Cytogenetics’ impact on the prognosis of acute myeloid leukemia
INTRODUCTION: Acute myeloid leukemia (AML) is a group of disorders characterized by a spectrum of clinical, morphological, immunophenotypic, and associated chromosomal abnormalities. The identification of cytogenetic abnormalities at diagnosis is important for the evaluation of the response to thera...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543945/ https://www.ncbi.nlm.nih.gov/pubmed/31160852 http://dx.doi.org/10.4103/JLP.JLP_164_18 |
_version_ | 1783423170656600064 |
---|---|
author | Gupta, Monika Mahapatra, Manoranjan Saxena, Renu |
author_facet | Gupta, Monika Mahapatra, Manoranjan Saxena, Renu |
author_sort | Gupta, Monika |
collection | PubMed |
description | INTRODUCTION: Acute myeloid leukemia (AML) is a group of disorders characterized by a spectrum of clinical, morphological, immunophenotypic, and associated chromosomal abnormalities. The identification of cytogenetic abnormalities at diagnosis is important for the evaluation of the response to therapy and the identification of an early reemergence of disease. MATERIALS AND METHODS: Newly diagnosed cases of AML were included in the study. Diagnosis of AML was based on morphology on bone marrow (BM) aspirates, cytochemistry, and flow cytometric immunophenotyping. Chromosomal analysis was performed on BM by short-term unstimulated cultures using standard cytogenetic technique. RESULTS: There were 25 males and 13 females with age group between 15 and 64 years. Cytogenetic analysis of these cases showed normal karyotype in 10 (26.3%) cases and abnormal karyotype in 28 (73.6%) cases. Cytogenetic finding in AML was divided into three groups: favorable risk, intermediate risk, and unfavorable risk. Patients in the standard risk group responded well to the chemotherapy while patients with intermediate and unfavorable karyotype had relapsed. CONCLUSION: We recommend that cytogenetics should be performed routinely in all cases of AML. A correlation must be done with various biochemical and hematological parameters, immunophenotyping, and BM morphology. Molecular studies must be integrated with cytogenetic studies for risk stratification at diagnosis to improve therapeutic strategies. |
format | Online Article Text |
id | pubmed-6543945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-65439452019-06-03 Cytogenetics’ impact on the prognosis of acute myeloid leukemia Gupta, Monika Mahapatra, Manoranjan Saxena, Renu J Lab Physicians Original Article INTRODUCTION: Acute myeloid leukemia (AML) is a group of disorders characterized by a spectrum of clinical, morphological, immunophenotypic, and associated chromosomal abnormalities. The identification of cytogenetic abnormalities at diagnosis is important for the evaluation of the response to therapy and the identification of an early reemergence of disease. MATERIALS AND METHODS: Newly diagnosed cases of AML were included in the study. Diagnosis of AML was based on morphology on bone marrow (BM) aspirates, cytochemistry, and flow cytometric immunophenotyping. Chromosomal analysis was performed on BM by short-term unstimulated cultures using standard cytogenetic technique. RESULTS: There were 25 males and 13 females with age group between 15 and 64 years. Cytogenetic analysis of these cases showed normal karyotype in 10 (26.3%) cases and abnormal karyotype in 28 (73.6%) cases. Cytogenetic finding in AML was divided into three groups: favorable risk, intermediate risk, and unfavorable risk. Patients in the standard risk group responded well to the chemotherapy while patients with intermediate and unfavorable karyotype had relapsed. CONCLUSION: We recommend that cytogenetics should be performed routinely in all cases of AML. A correlation must be done with various biochemical and hematological parameters, immunophenotyping, and BM morphology. Molecular studies must be integrated with cytogenetic studies for risk stratification at diagnosis to improve therapeutic strategies. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6543945/ /pubmed/31160852 http://dx.doi.org/10.4103/JLP.JLP_164_18 Text en Copyright: © 2019 Journal of Laboratory Physicians http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Gupta, Monika Mahapatra, Manoranjan Saxena, Renu Cytogenetics’ impact on the prognosis of acute myeloid leukemia |
title | Cytogenetics’ impact on the prognosis of acute myeloid leukemia |
title_full | Cytogenetics’ impact on the prognosis of acute myeloid leukemia |
title_fullStr | Cytogenetics’ impact on the prognosis of acute myeloid leukemia |
title_full_unstemmed | Cytogenetics’ impact on the prognosis of acute myeloid leukemia |
title_short | Cytogenetics’ impact on the prognosis of acute myeloid leukemia |
title_sort | cytogenetics’ impact on the prognosis of acute myeloid leukemia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543945/ https://www.ncbi.nlm.nih.gov/pubmed/31160852 http://dx.doi.org/10.4103/JLP.JLP_164_18 |
work_keys_str_mv | AT guptamonika cytogeneticsimpactontheprognosisofacutemyeloidleukemia AT mahapatramanoranjan cytogeneticsimpactontheprognosisofacutemyeloidleukemia AT saxenarenu cytogeneticsimpactontheprognosisofacutemyeloidleukemia |